A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
← catalyst calendarNCT05259709 · readout in 139 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
50estimated
Sites
1
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-07 | actual | When the study began enrolling |
| Primary completion | 2027-01-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-06 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
- Drug: 89Zr˗DFO˗REGN5054
- Drug: cemiplimab — also filed as REGN2810, Libtayo
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of treatment-emergent adverse events (TEAEs)
measured Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
Incidence and severity of TEAEs
measured Up to approximately week 115
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed